Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SGAustria is a biotechnology company based in Austria that focuses on the development of innovative peptide-based therapeutics targeting metabolic and gastrointestinal disorders. The company leverages its expertise in G protein-coupled receptor (GPCR) signaling to design highly specific agonists and antagonists for receptors such as the secretin and glucagon-like peptide receptors. Their primary research efforts are directed toward addressing unmet medical needs in conditions like short bowel syndrome and metabolic syndrome. SGAustria operates as a lean, research-driven entity, often collaborating with academic institutions to advance its early-stage pipeline. The company's lead programs are currently in the pre-clinical phase, aiming to optimize drug delivery and efficacy profiles.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on SGAustria.